TRexBio Announces Pricing of Initial Public Offering

Impact · against what's priced in

TRexBio has established its initial market valuation and secured approximately $116.7 million in funding to support its clinical-stage R&D. The IPO provides a concrete valuation benchmark and operational runway for the company, while generating standard fee income for its lead underwriters, including J.P. Morgan.

TRXB+0.80: No priced-in read yet
In context: The pricing of the IPO at $14.00 per share and the expected gross proceeds of $116.7 million provide the company with necessary capital for clinical milestones and establish its first public valuation.
Read from the article alone

TRexBio Announces Pricing of Initial Public Offering

healthcare
pharmaceuticals
ipo
JPM
TRXB
biotechnology
clinical stage
immunoregulatory
nasdaq

Search tags

TRexBio Announces Pricing of Initial Public Offering

What matters in this story

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

TRexBio Announces Pricing of Initial Public Offering

What matters in this story

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

How each ticker is affected

Connected tickers

Track these names every morning.

AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL

Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline

TRexBio Announces Pricing of Initial Public Offering

What matters in this story

Next reads from the same story arc

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

TRexBio Announces Pricing of Initial Public Offering

What matters in this story

Next reads from the same story arc

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

How each ticker is affected

Connected tickers

Track these names every morning.

AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL

Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline